ArticleArquivos de gastroenterologia2025
INTERLEUKIN-6 AND INTERLEUKIN-10 AS BIOMARKERS OF HEPATOCELLULAR CARCINOMA PROGRESSION: A CROSS-SECTIONAL ANALYSIS OF NUTRITIONAL, CYTOKINE AND SURVIVAL PARAMETERS.
Article in Arquivos de gastroenterologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- THE IL-6/IL-10 INFLAMMATORY AXIS AND PROGNOSIS OF CIRRHOSIS-ASSOCIATED HEPATOCELLULAR CARCINOMA: A NARRATIVE REVIEW.Arquivos de gastroenterologia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the leading cause of mortality among cirrhotic patients, often linked to advanced liver disease.
objectiveThis cross-sectional study evaluated the nutritional factors, cytokine profiles, liver function parameters, and survival of patients with liver cirrhosis (LC) and HCC.
methodsForty-seven patients were grouped as LC (n=21) or LC with HCC (n=26). Nutritional status was assessed through anthropometry, bioelectrical impedance analysis, and dietary recall, while cytokine levels (IL-6, IL-10, TNF-α) and biochemical markers (AST, ALT, albumin, prealbumin) were analyzed. Survival data were evaluated using Kaplan-Meier curves and Cox regression.
resultsHCC patients exhibited higher IL-6 levels, correlating with advanced disease stages (P=0.035). IL-10 levels were elevated in early-stage HCC (BCLC A) compared to BCLC B (P=0.006). AST and ALT levels were significantly higher in HCC patients, reflecting greater hepatocyte damage. Survival analysis revealed a median of 756 days, with shorter survival in HCC patients (P=0.0172).
conclusionThis study highlights the roles of IL-6 and IL-10 as potential biomarkers in HCC progression and provides critical insights into the biochemical and nutritional profiles associated with LC and HCC. These findings may inform future therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.